Keating Financial Advisory Services’s KalVista Pharmaceuticals KALV Stock Holding History

Keating Financial Advisory Services’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16	Closed	-$322	–	2665
2026 Q1	$322	Buy	+16	New	+$258	﹤0.01%	2326

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Keating Financial Advisory Services's KALV Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 16 shares — an estimated $322 sold.

Keating Financial Advisory Services first reported a position in KALV in Q1 2026 and held it in 1 quarter. The position peaked at $322 in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Keating Financial Advisory Services reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Keating Financial Advisory Services sold 16 KalVista Pharmaceuticals shares in Q2 2026, an estimated $322.
Keating Financial Advisory Services first reported a position in KalVista Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Keating Financial Advisory Services's KalVista Pharmaceuticals position peaked at $322 in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.